Citation

Sesso G, Masi G. Expert Rev Clin Pharmacol 2023; ePub(ePub): ePub.

Copyright

(Copyright © 2023, Informa Healthcare)

DOI

10.1080/17512433.2023.2181159

PMID

36787887

Abstract

INTRODUCTION: : Antisocial personality disorder (AsPD) is a pervasive pattern of violation of others' rights, related to the concept of psychopathy. AsPD is stable over time from adolescence, with evidence of conduct disorder (CD) before 15 years. DSM-5 included a specifier "with limited prosocial emotions" (LPE), which characterizes adolescents with higher developmental vulnerability to develop AsPD. Though being relatively frequent with considerable societal impact, AsPD is a difficult-to-treat condition with high comorbidity rates and poor evidence for effective pharmacological interventions. AREAS COVERED: : We conducted a narrative review and searched PubMed up to September 2022. We included RCTs and naturalistic studies evaluating pharmacological interventions on AsPD in adults, including those with comorbid substance use disorder or psychopathic traits. Evidence in youths with CD, callous-unemotional (CU) traits and aggression were also reviewed, exploring the role of CU traits as moderators of response.

EXPERT OPINION: Psychosocial interventions are the first option, with possible improvement of CU traits, beyond behavioral and affective symptoms, particularly if implemented early during development. Limited information, based on low-quality studies, supports the pharmacological options. Second generation antipsychotics, lithium, anti-epileptic drugs, and stimulants are first-line medications, according to different target symptoms. Developmental pathways including ADHD suggest a specific role of psychostimulants.

Language: en

Keywords

antisocial personality disorder; callous-unemotional traits; conduct disorder; mood stabilizers; psychopathic personality; psychostimulants; second generation antipsychotics